![]() |
市場調查報告書
商品編碼
1754279
2025 年至 2033 年糖尿病護理設備市場規模、佔有率、趨勢及預測(按類型、配銷通路、最終用戶和地區)Diabetes Care Devices Market Size, Share, Trends and Forecast by Type, Distribution Channel, End User, and Region, 2025-2033 |
2024年,全球糖尿病護理設備市場規模達341.9億美元。展望未來, IMARC Group預測,到2033年,該市場規模將達到626.5億美元,2025年至2033年的複合年成長率為6.61%。北美目前佔據市場主導地位,2024年的市佔率將超過38.6%。糖尿病發病率的上升、技術的快速進步、政府優惠政策的實施、可支配收入的增加、巨量資料與分析技術的融合以及老年人口的不斷成長,是推動市場發展的主要因素。
全球糖尿病照護設備市場的成長是由人口老化、久坐不動的生活方式以及不良飲食習慣導致的糖尿病發病率上升所引發的。都市化進程的加速伴隨著肥胖率的上升。持續血糖監測 (CGM) 系統、智慧胰島素筆和閉迴路胰島素輸送等先進技術有助於提高患者的依從性和療效。政府在提高糖尿病認知度和早期診斷方面的努力也刺激了市場的發展,尤其是在醫療基礎設施不斷完善的新興經濟體。例如,美敦力於2024年8月獲得美國食品藥物管理局 (FDA) 批准其 Simplera™ CGM(一款一次性一體化設備),並宣布與雅培建立全球合作夥伴關係,以擴展持續血糖監測 (CGM) 解決方案。此外,人工智慧 (AI) 和基於雲端的資料分析技術推動了糖尿病管理解決方案的發展,從而提高了遠端監控能力。發展中經濟體不斷成長的可支配收入和醫療保健支出促進了先進糖尿病護理設備的普及。報銷政策和法規核准也加速了創新和商業化。遠距醫療和數位糖尿病管理平台的進步帶來了新的成長機會,尤其是遠距患者監控在慢性病管理中變得越來越重要。
美國糖尿病護理設備市佔率達89.5%,這得益於患者對居家糖尿病管理解決方案的需求不斷成長,這些解決方案可減少患者就診次數。例如,Dexcom於2024年8月推出了Stelo,這是美國首款非處方血糖生物感測器,可為第二型糖尿病患者和糖尿病前期患者提供全天候血糖監測,無需處方或指尖採血。此外,完善的醫療基礎設施、研究設施和完善的報銷政策也為新型糖尿病管理設備和解決方案的使用提供了支援。美國對連續血糖監測(CGM)設備的需求很高,尤其是胰島素依賴型患者,因為醫療保險和私人保險都涵蓋此類設備。關鍵產業參與者的存在,加上美國食品藥物管理局(FDA)的定期產品核准,促進了技術的快速發展。消費者對微創、方便用戶使用且具有治療益處的設備日益成長的認知和偏好,推動了市場成長。行動應用程式和基於人工智慧的糖尿病管理工具等數位健康解決方案的廣泛應用,提升了患者的參與度。妊娠糖尿病和糖尿病前期盛行率的上升進一步擴大了需求量。公私合作和研究資助推動了持續創新,增強了市場競爭格局。
糖尿病發生率上升
糖尿病盛行率的上升是推動糖尿病護理設備市場成長的主要因素。這種成長主要源自於各種生活方式的改變,包括久坐不動的習慣以及高糖高脂飲食的增加。此外,隨著糖尿病病例數量的增加,對高效管理和監測工具的需求變得比以往任何時候都更加迫切。 2021年,全球約有5.37億成年人患有糖尿病,國際糖尿病聯盟估計,這一數字將持續上升,到2045年將達到7.83億。因此,糖尿病照護設備被廣泛用於改善血糖管理、最大限度地降低併發症風險、減少急診就診次數、改善患者預後,並提供即時資料以便快速決策。此外,高發病率也提高了人們對糖尿病的認知和緊迫感,從而鼓勵人們加強對研發和創新的投入,以加快技術進步的步伐,使市場對潛在買家更具吸引力。
快速的技術進步
糖尿病護理設備市場正受到快速技術進步的影響,這些技術提高了精準度、易用性和便利性。連續血糖監測系統引入了 CGM,它可以觀察患者的連續血糖曲線並提供即時血糖監測,從而增強治療客製化和生活方式調整,從而對該市場的成長產生了積極影響。根據一份產業報告,預計到 2028 年,CGM 市場銷售額將達到 200 億美元。此外,智慧胰島素筆配備劑量計算器,透過消除實際胰島素劑量中的所有猜測,將高度複雜化,也促進了該市場的成長。此外,配備連接功能的創新設備的開發,使醫護人員和患者之間能夠無縫共享資料,也有利於市場成長。
實施優惠的政府舉措
公共衛生政策和政府措施在糖尿病護理設備市場的成長中發揮重要作用。一些政府已經意識到糖尿病對醫療保健系統的負擔,並採取積極措施加以應對。據世界衛生組織稱,2021年,「全球有超過4.22億人患有糖尿病,估計其在全球範圍內造成的經濟負擔約為1.3兆美元。」 市場成長得益於一些組織開展宣傳活動的機構,這些機構旨在向公眾提供有關糖尿病風險和各種疾病管理方法的建議。此外,一些政府加大了對糖尿病護理設備成本的補貼力度,使更多民眾能夠負擔得起這些設備,這也促進了市場的成長。此外,各種報銷計畫的推出,涵蓋了持續血糖監測儀(CGM)等先進設備的成本,也促進了市場的成長。
The global diabetes care devices market size was valued at USD 34.19 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 62.65 Billion by 2033, exhibiting a CAGR of 6.61% from 2025-2033. North America currently dominates the market, holding a market share of over 38.6% in 2024. The rising incidences of diabetes, rapid technological advancements, imposition of favorable government initiatives, increasing disposable incomes, integration of big data and analytics, and escalating geriatric population are some of the major factors propelling the market.
The growing global market for diabetes care devices is triggered by a geriatric population, increasingly sedentary lifestyle, and poor diets leading to higher levels of diabetes cases. The urbanization pace continues to rise in conjunction with higher rates of obesity. Advanced technology in continuous glucose monitoring (CGM) systems, smart insulin pens, and closed-loop insulin delivery contributes to greater compliance and outcomes from the patients' end. Government efforts toward escalating diabetes awareness and early diagnosis also spur the market, especially in emerging economies with an improving healthcare infrastructure. For instance, in August 2024, Medtronic received FDA approval for its Simplera(TM) CGM, a disposable, all-in-one device, and announced a global partnership with Abbott to expand continuous glucose monitoring (CGM) solutions. Moreover, diabetes management solutions are surged by artificial intelligence (AI) and cloud-based data analytics for better remote monitoring capabilities. Rising disposable income and health care spending in developing economies enhance the adoption of advanced diabetes care devices. Reimbursement policies and regulatory approvals also speed up innovation and commercialization. The advancements in telehealth and in digital diabetes management platforms hold new growth opportunities, especially with remote patient monitoring becoming more critical in the management of chronic diseases.
The U.S. diabetes care devices market share is 89.5% owing to the accelerating demand from patients preferring home-based diabetes management solutions which will reduce their hospital visits. For example, in August 2024, Dexcom launched Stelo, the first over-the-counter glucose biosensor in the U.S., providing 24/7 glucose insights without prescriptions or fingersticks for individuals with Type 2 diabetes and prediabetes. Furthermore, well-developed healthcare infrastructure, research facilities, and established reimbursement policies support the use of novel diabetes management devices and solutions. The demand for CGM devices is high in the country, especially in the case of insulin-dependent patients, since Medicare as well as private insurances cover such devices. The presence of key industry players, combined with regular product approvals by the U.S. FDA, favors fast-paced technological development. Heightened consumer awareness and preference for devices that are minimally invasive, user-friendly, and support therapeutic benefits drive market growth. Greater adoption of digital health solution-based solutions, such as mobile apps and AI-based diabetes management tools, enhance patient engagement. The rising prevalence of gestational diabetes and prediabetes further amplifies the volume of demand. Public-private partnerships and research grants fuel continuous innovation, strengthening the market's competitive landscape.
The Rising Incidence of Diabetes
The increasing prevalence of diabetes is a dominant factor fueling the diabetes care devices market growth. This escalation is primarily caused by various lifestyle changes, including sedentary habits and increasing consumption of high-sugar and high-fat diets. Furthermore, as the number of diabetes cases multiplies, the need for efficient management and monitoring tools becomes more critical than ever. In 2021, around 537 million adults worldwide have diabetes, a number that the International Diabetes Federation estimates will continue to rise and reach 783 million by 2045. In line with this, diabetes care devices are widely used to improve glucose management, minimize the risks of complications, reduce emergency healthcare visits, increase patient outcomes, and provide real-time data for quick decision-making. Moreover, the high incidence rates lead to greater awareness and urgency, thereby encouraging more investments in research and innovation efforts to accelerate the pace of technological advancements, making the market even more attractive to potential buyers.
The Rapid Technological Advancements
The diabetes care devices market is being shaped by rapid technological advancements that offer improved precision, ease of use, and convenience. Continuous glucose monitoring systems are introducing CGMs, which observe the continuous glucose profile of a patient and provide real-time glucose monitoring, enhancing treatment customization and lifestyle adjustments that are positively influencing the growth in this market. According to an industry report, the CGM market is expected to capture sales of USD 20 Billion by 2028. Additionally, in smart insulin pens having dose calculators, which are nothing but the incorporation of high sophistication by eliminating all the guesswork in the actual dosing of insulin, is contributing toward this market growth as well. Additionally, the development of innovative devices that are equipped with connectivity features, enabling seamless data sharing between healthcare professionals and patients, is favoring the market growth.
The Imposition of Favorable Government Initiatives
Public health policies and government initiatives play a significant role in the growth of the diabetes care devices market. Several governments are recognizing the burden that diabetes imposes on healthcare systems and are taking proactive measures to address it. According to WHO, in 2021, "over 422 million people across the world were suffering from this disease, which is estimated at around USD 1.3 trillion in its economic burden throughout the world globally." In continuation of this point, the marketing growth is contributed by organizations that organize information campaigns to advise the public in relation to a risk of encountering diabetes and various ways of disease management. Moreover, the increasing allocation of funds by several governments to subsidize the cost of diabetes care devices, making them more accessible to a broader population, is contributing to the market growth. Besides this, the introduction of various reimbursement schemes to cover the cost of advanced devices, such as continuous glucose monitoring (CGMs) is contributing to the market growth.
Blood Glucose Monitoring (BGM) leads the market with around 65.8% of market share in 2024. These devices are dominating the market as they are highly affordable, making them accessible to a broader range of consumers. Furthermore, they are designed for user-friendliness, often requiring just a small drop of blood for accurate glucose readings. Additionally, BGM devices offer near-instantaneous results, enabling immediate action if needed, such as adjusting insulin dosage or food intake. Besides this, they are compact and easy to carry, making them convenient for people who are always on the go. This portability ensures that monitoring can happen anytime, anywhere. Moreover, BGM devices are being used for a longer period and enjoy broad acceptance among healthcare providers. In addition, they require minimal upkeep, usually replacement of test strips and occasional calibration, which makes them convenient for long-term use.
Hospital pharmacies lead the market with around 54.7% of market share in 2024. These are dominating the market as they are considered reliable and trustworthy sources for medical devices, including those for diabetes care. Furthermore, patients admitted for diabetes complications or those visiting for a routine check-up can quickly and conveniently purchase the required devices and supplies from the hospital pharmacy. In addition, they employ well-trained pharmacists who can provide expert advice on device usage, thereby adding an extra layer of reassurance for patients. Besides this, products sold in hospital pharmacies are generally subject to rigorous quality checks, ensuring that patients receive authentic and effective devices. Moreover, they offer a streamlined process for insurance claims and reimbursements, making it easier for patients to offset the costs of their diabetes care devices. Along with this, hospital pharmacies offer a comprehensive range of diabetes care devices, giving patients various options to choose from.
Hospitals leads the market with around 40.5% of market share in 2024, as they offer a one-stop solution for all medical needs, making it easier for patients to get all their diabetes-related services, including consultations, treatments, and devices. Furthermore, they employ specialists in endocrinology and diabetes care, ensuring that patients receive expert advice and treatment. In addition, hospitals have the resources to handle diabetes-related emergencies, such as diabetic ketoacidosis, which standalone clinics may not be equipped for. Apart from this, hospital-based care is often covered by insurance plans, making it a more accessible option for many patients. Moreover, the sheer number of patients that hospitals serve ensures that they purchase diabetes care devices in bulk, thus contributing to their large share of the market. Along with this, they are subjected to strict quality control standards, which provide assurance of the efficacy and safety of the diabetes care devices used.
In 2024, North America accounted for the largest market share of over 38.6%. The region has one of the highest rates of diabetes in the world, which leads to increased demand for diabetes care devices. Furthermore, the region boasts a well-developed healthcare system with widespread availability of advanced medical technologies, including diabetes care devices. Additionally, the presence of comprehensive insurance plans, which cover diabetes treatment and devices, making it convenient for patients to access the care they need, is positively influencing the market growth. Besides this, North America hosts some of the leading companies in medical device manufacturing that are continuously updating and advancing diabetes care technology. In addition, the escalating awareness about diabetes and its management among regional consumers is acting as another growth-inducing factor. Moreover, the imposition of supportive policies and initiatives by regional governments to combat diabetes and provide access to high-quality treatment is favoring the market growth.
United States Diabetes Care Devices Market Analysis
The U.S. diabetes care devices market is increasing steadily due to the prevalence of diabetes and high healthcare expenditures. According to the CDC, around 37.3 million people in America suffer from diabetes, and this makes 11.3% of the total population in the United States. This raised number is raising the demand for diabetes management products. In 2023, an estimated amount of USD 327 billion were spent on U.S. healthcare on diabetes care, most of which goes into medical devices, including CGMs and insulin pumps. Leading players in this market are Medtronic, Abbott, and Dexcom, which are moving the technologies along to include the integrated insulin delivery systems. The continued efforts towards accessibility and affordability of diabetes devices will further drive the market growth. As the country continues to push for integration of digital health, telemedicine for diabetes care is expected to augment device adoption, ensuring continued momentum in the market.
Europe Diabetes Care Devices Market Analysis
The market for diabetes care devices is increasing in Europe with increasing prevalence of diabetes and increased investment in health. IDF states that 2023 was the year when more than 60 million people were living with diabetes in Europe. Germany and UK are well ahead in using advanced diabetes care devices. These include insulin pens, CGMs, and insulin pumps. Further, cost-effective health care seems to be creating growth opportunities for the European as well as EU-wide markets. There is a wide effort to curb chronic diseases that is also working for the industry's growth. Smart insulin pens, wireless glucose monitoring systems are other innovative products coming from leaders such as Roche and Bayer. The regulation framework in Europe about diabetes care products, safety and effectiveness in treatment, facilitates the innovation in market growth.
Asia Pacific Diabetes Care Devices Market Analysis
Asia Pacific diabetes care devices market is highly growing due to the increasing diabetes rates and geriatric population. IDF reports that more than 170 million people are suffering from diabetes, and the population of China and India is leading in this segment. An industrial report suggests that China's diabetes care market was at USD 4.7 billion in 2023, and considerable investments have been made into the advanced medical devices, which include CGMs and insulin delivery systems. In India, the diabetes care device markets also grow as more emphasis is being put upon cost-effective and affordable solutions. Healthcare infrastructure growth and adoption of digital health solutions have spurred the demand for diabetes devices in this region. Innovation and access to products is also driven through partnerships between international and local players, such as Abbott and Medtronic collaborating in India. Government-backed programs for increasing the accessibility of better diabetes care in the region continue to fuel the growth of this market.
Latin America Diabetes Care Devices Market Analysis
In terms of the high prevalence of diabetes in Latin America, Brazil accounts for over 15.7 million adults who are already affected, a figure provided by the International Diabetes Federation (IDF) of 2021. This explains why the high prevalence of the disease has driven up healthcare costs in the country. As per industrial reports, in 2021, a total of 42.93 billion USD had been allocated toward diabetes care within Brazil. Given the trend this amount is believed to increase profoundly in the forthcoming years, surging to a total of about 48.31 billion in 2030 and 51.44 billion in 2045. In other words, it is directly proportional to increasing disease burden. Moreover, the Brazilian government tries to expand the use of advanced technologies in the treatment of very high medical specialties like insulin pumps, continuous glucose monitors (CGMs), and insulin pens, along with expanding the public knowledge and patient's perception. The overall approach to that is driven by Novo Nordisk, Sanofi, and other key market players with very critical treatment options and increasingly adequate technologies for satisfying the present demand.
Middle East and Africa Diabetes Care Devices Market Analysis
The International Diabetes Federation (IDF) estimates around 73 million adults in the Middle East and North Africa, also known as the MENA region. The statistics show that the prevalence among adults in Saudi Arabia is nearly 17.7%, and about 4.27 million people are diagnosed with diabetes in the country, while South Africa is also the region's 'hot spot'. This boosting trend is due to the growing diabetes care market in the country. Current government action, such as healthcare initiatives that offer cheap access to diabetes care equipment, has been proved to impact the aspect comprehensively. Saudi Arabia has also accentuated the healthcare infrastructure, and campaigns to educate the people about diabetes management. Therefore, the diabetes care market in Saudi Arabia is growing, as demand for insulin pumps and continuous glucose monitoring (CGM) devices is increasing along with other advanced solutions for efficient management of the disease.
Leadership companies are moving towards bringing next-generation products in the pipeline to market, such as smart insulin pens, CGM integrated devices and much accurate meters for checking the blood sugar. Additionally, major companies are developing partnership arrangements with health-care organisations, IT organizations and sometimes, competitors for designing new devices jointly. Moreover, key companies have developed differentiated product lines which suit emerging geographies where the risk of developing the disease is escalating. They are also integrating digital technologies, such as data analytics and telehealth, into their devices to allow real-time monitoring and data collection, which can be crucial for effective diabetes management. Several companies are investing in education programs and materials to help users understand how to manage diabetes effectively. Along with this, they are leveraging online platforms for direct sales and customer engagement.